Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Work
Year: 2013
Type: article
Abstract: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously kno... more
Source: New England Journal of Medicine
Institutions Angeles Clinic and Research Institute, Institut Gustave Roussy, University of California, San Francisco, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center +14 more
Cites: 17
Cited by: 3,304
Related to: 10
FWCI: 233.8
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze